A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
Authors
Keywords
Synovial sarcoma, Radioimmunotherapy, Theranostic, First-in-human trial
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-06-08
DOI
10.1186/s12885-018-4544-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
- (2016) U. Haberkorn et al. CLINICAL CANCER RESEARCH
- Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
- (2016) David Rizzieri CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity
- (2016) Myrella Vlenterie et al. EUROPEAN JOURNAL OF CANCER
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
- (2016) H. R. Kulkarni et al. JOURNAL OF NUCLEAR MEDICINE
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
- (2016) Hojjat Ahmadzadehfar et al. Oncotarget
- Pazopanib in the management of advanced soft tissue sarcomas
- (2016) Lee Cranmer et al. Therapeutics and Clinical Risk Management
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
- (2013) John J. Zaknun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Chromosome Instability Accounts for Reverse Metastatic Outcomes of Pediatric and Adult Synovial Sarcomas
- (2013) Pauline Lagarde et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic approaches for the treatment of advanced synovial sarcomas
- (2012) Khanh Do et al. CURRENT OPINION IN ONCOLOGY
- THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience
- (2012) Richard P. Baum et al. Theranostics
- Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
- (2011) Françoise Ducimetière et al. PLoS One
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
- (2009) Stefan Sleijfer et al. EUROPEAN JOURNAL OF CANCER
- Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10
- (2008) Chikako Fukukawa et al. CANCER SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started